The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.
Muzaffar H. Qazilbash
Honoraria - Otsuka
Research Funding - Otsuka
Peter F. Thall
No relevant relationships to disclose
Patricia S Fox
No relevant relationships to disclose
Partow Kebriaei
No relevant relationships to disclose
Qaiser Bashir
No relevant relationships to disclose
Nina Shah
No relevant relationships to disclose
Borje Andersson
Consultant or Advisory Role - Otsuka
Research Funding - Otsuka; Sanofi
Yago Nieto
No relevant relationships to disclose
Ben Valdez
No relevant relationships to disclose
Simrit Parmar
No relevant relationships to disclose
Yvonne Dinh
No relevant relationships to disclose
Chitra Hosing
No relevant relationships to disclose
Uday R. Popat
Research Funding - Otsuka
Jatin J. Shah
Honoraria - Array BioPharma; Celgene; Millennium; Novartis; Onyx
Research Funding - Array BioPharma; Celgene; Millennium; Novartis; Onyx
Robert Z. Orlowski
Honoraria - Array BioPharma; Bristol-Myers Squibb; Celgene; Genentech; Millennium; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Onyx; Resverlogix
Richard E. Champlin
No relevant relationships to disclose